Cargando…
Spotlight on ponatinib in the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia: patient selection and perspectives [Erratum]
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6467342/ https://www.ncbi.nlm.nih.gov/pubmed/31360089 http://dx.doi.org/10.2147/BLCTT.S169529 |
Ejemplares similares
-
Spotlight on ponatinib in the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia: patient selection and perspectives
por: Anagnostou, Theodora, et al.
Publicado: (2017) -
Monitoring Ponatinib in a Child with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
por: Tanimura, Kazuki, et al.
Publicado: (2021) -
Ponatinib, chemotherapy, and transplant in adults with Philadelphia chromosome–positive acute lymphoblastic leukemia
por: Ribera, Josep-Maria, et al.
Publicado: (2022) -
Potential of ponatinib to treat chronic myeloid leukemia and acute lymphoblastic leukemia
por: Price, Kimberly E, et al.
Publicado: (2013) -
Therapeutic potential of ruxolitinib and ponatinib in patients with EPOR-rearranged Philadelphia chromosome-like acute lymphoblastic leukemia
por: Niswander, Lisa M., et al.
Publicado: (2021)